Literature DB >> 25974289

40 Years of the APOC Partnership.

Jean-Baptist Roungou1, Laurent Yameogo1, Chris Mwikisa1, Daniel A Boakye1, Donald A P Bundy2.   

Abstract

Entities:  

Year:  2015        PMID: 25974289      PMCID: PMC4431867          DOI: 10.1371/journal.pntd.0003562

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


× No keyword cloud information.
The fight against onchocerciasis (river blindness), one of the most devastating neglected tropical diseases (NTDs), has mobilized significant resources and brought together diverse public and private stakeholders. Affected communities, governments of endemic countries, non-governmental development organizations (NGDOs), donors, and researchers are contributing, each in their own way, to what is considered today as one of the major public health achievements of recent decades in Africa [1]. Onchocerciasis is losing ground, and its elimination in Africa is now possible within a reasonable timeframe [2,3]. Onchocerciasis is a vector-borne disease caused by the filarial worm Onchocerca volvulus. The Onchocerciasis Control Programme in West Africa (OCP), launched in 1974, initially focused its activities on vector control in 11 West African countries and invested US$556 million over 28 years [4]. OCP succeeded in controlling river blindness in ten countries, with an amazing 20% economic rate of return [5]. In 1987, in light of demonstrated ivermectin efficacy and safety in humans, Merck & Co. Inc. committed to providing the medicine free of charge to endemic countries for as long as necessary to eliminate river blindness as a public health problem. This historic pledge enabled a new era in river blindness control through mass drug administration [6]. Building upon OCP, the African Programme for Onchocerciasis Control (APOC) was launched in 1995 to extend the gains in river blindness control achieved in West Africa to the 19 remaining endemic countries, mainly located in central and eastern Africa. APOC adopted the community-directed treatment with ivermectin (CDTi) approach as its core strategy. The effectiveness of CDTi in improving coverage and compliance has since been demonstrated, and it is now used as a model for scaling up other public health interventions [7]. APOC’s work is underpinned by four main pillars: (i) ivermectin donation by Merck; (ii) commitment to the CDTi strategy; (iii) a unique partnership among the affected communities, governments, donors, NGDOs, and APOC Secretariat; and (iv) continued scientific (basic and operational) research, results of which were immediately ploughed in to improve performance. Structures and mechanisms have been set up to implement, manage, and review this work. APOC’s work translates on the ground into CDTi projects, which were 107 in 2012. The CDTi projects deliver ivermectin once a year to the affected and at-risk communities. These communities are fully empowered to play their role: they select community-directed ivermectin distributors (CDDs), decide on the most suitable period for ivermectin mass distribution, monitor ivermectin distribution and provide incentives to CDDs, and report treatment adverse effects to the nearest health facilities. On their side, the health workers who are trained by experts from APOC and in-country consultants ensure training of CDDs and their supervision; they help with management of ivermectin supply and take charge of responding to severe adverse effects of ivermectin treatment. This way, CDTi enormously contributes to primary health care implementation. The control of river blindness has been a remarkable success story. Now the focus has shifted to a more ambitious goal: the elimination of river blindness in addition to other preventable NTDs from Africa. To help endemic countries achieve this aim, plans are underway to transition APOC into a new regional NTD entity, provisionally named Programme for the Elimination of Neglected Tropical Diseases (PENDA), in 2016. As river-blindness–endemic countries in Africa engage in the elimination of the disease and APOC transforms into a new regional entity, it is important to widely share the APOC partnership experience. This series of articles will highlight the different aspects of the fight, focusing on the history and governance of APOC, the management of the ivermectin donation [8], the technical foundations of the work of APOC, the country programs and perspectives, NGDOs action [9], mechanisms for financial sustainability [10], and the future of regional NTD elimination efforts.
  6 in total

1.  Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health.

Authors:  Kimberly Collins
Journal:  Perspect Biol Med       Date:  2004       Impact factor: 1.416

Review 2.  Onchocerciasis control and elimination: coming of age in resource-constrained health systems.

Authors:  David H Molyneux
Journal:  Trends Parasitol       Date:  2005-09-09

3.  Investing in Onchocerciasis Control: Financial Management of the African Programme for Onchocerciasis Control (APOC).

Authors:  Donald A P Bundy; Bilkiss Dhomun; Xavier Daney; Linda B Schultz; Andy Tembon
Journal:  PLoS Negl Trop Dis       Date:  2015-05-14

4.  From River Blindness to Neglected Tropical Diseases--Lessons Learned in Africa for Programme Implementation and Expansion by the Non-governmental Partners.

Authors:  Catherine Cross; Franca Olamiju; Frank Richards; Simon Bush; Adrian Hopkins; Danny Haddad
Journal:  PLoS Negl Trop Dis       Date:  2015-05-14

5.  Growth, Challenges, and Solutions over 25 Years of Mectizan and the Impact on Onchocerciasis Control.

Authors:  Joni Lawrence; Yao K Sodahlon; Kisito T Ogoussan; Adrian D Hopkins
Journal:  PLoS Negl Trop Dis       Date:  2015-05-14

6.  Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.

Authors:  Lamine Diawara; Mamadou O Traoré; Alioune Badji; Yiriba Bissan; Konimba Doumbia; Soula F Goita; Lassana Konaté; Kalifa Mounkoro; Moussa D Sarr; Amadou F Seck; Laurent Toé; Seyni Tourée; Jan H F Remme
Journal:  PLoS Negl Trop Dis       Date:  2009-07-21
  6 in total
  9 in total

1.  The PLOS Neglected Tropical Diseases decade.

Authors:  Peter Hotez; Donald A P Bundy
Journal:  PLoS Negl Trop Dis       Date:  2017-04-20

2.  PLOS Neglected Tropical Diseases: Ten years of progress in neglected tropical disease control and elimination … More or less.

Authors:  Peter Hotez; Serap Aksoy
Journal:  PLoS Negl Trop Dis       Date:  2017-04-20

3.  Economic evaluations of onchocerciasis interventions: a systematic review and research needs.

Authors:  Hugo C Turner; Martin Walker; Sébastien D S Pion; Deborah A McFarland; Donald A P Bundy; María-Gloria Basáñez
Journal:  Trop Med Int Health       Date:  2019-05-09       Impact factor: 2.622

Review 4.  Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.

Authors:  Gebremedhin Gebrezgabiher; Zeleke Mekonnen; Delenasaw Yewhalaw; Asrat Hailu
Journal:  Infect Dis Poverty       Date:  2019-07-04       Impact factor: 10.485

5.  Evaluation of mass treatment with ivermectin program reach and survey coverage for onchocerciasis elimination in selected endemic areas of Ethiopia.

Authors:  Gebremedhin Gebrezgabiher; Delenasaw Yewhalaw; Asrat Hailu; Zeleke Mekonnen
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

Review 6.  Research for new drugs for elimination of onchocerciasis in Africa.

Authors:  Annette C Kuesel
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-05-19       Impact factor: 4.077

7.  Feasibility of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test in onchocerciasis surveillance in Senegal.

Authors:  Yakou Dieye; Helen L Storey; Kelsey L Barrett; Emily Gerth-Guyette; Laura Di Giorgio; Allison Golden; Dunia Faulx; Michael Kalnoky; Marie Khemesse Ngom Ndiaye; Ngayo Sy; Malang Mané; Babacar Faye; Mamadou Sarr; Elhadji Mamadou Dioukhane; Roger B Peck; Philippe Guinot; Tala de Los Santos
Journal:  PLoS Negl Trop Dis       Date:  2017-10-03

8.  Long-lasting microbial larvicides for controlling insecticide resistant and outdoor transmitting vectors: a cost-effective supplement for malaria interventions.

Authors:  Guofa Zhou; Eugenia Lo; Andrew K Githeko; Yaw A Afrane; Guiyun Yan
Journal:  Infect Dis Poverty       Date:  2020-11-26       Impact factor: 4.520

9.  Comparison of community-led distribution of HIV self-tests kits with distribution by paid distributors: a cluster randomised trial in rural Zimbabwean communities.

Authors:  Euphemia Lindelwe Sibanda; Collin Mangenah; Melissa Neuman; Mary Tumushime; Constancia Watadzaushe; Miriam N Mutseta; Galven Maringwa; Jeffrey Dirawo; Katherine L Fielding; Cheryl Johnson; Getrude Ncube; Miriam Taegtmeyer; Karin Hatzold; Elizabeth Lucy Corbett; Fern Terris-Prestholt; Frances M Cowan
Journal:  BMJ Glob Health       Date:  2021-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.